Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | geminin, DNA replication inhibitor | Starlite/ChEMBL | No references |
Escherichia coli | penicillin-binding protein | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Mycobacterium tuberculosis | Possible penicillin-binding protein | Get druggable targets OG5_149948 | All targets in OG5_149948 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | Hypothetical 65.5 kDa Trp-Asp repeats containing protein F02E8.5 inchromosome X | geminin, DNA replication inhibitor | 209 aa | 176 aa | 27.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0226 | 0.2957 | 0.5 |
Trypanosoma brucei | protein kinase, putative | 0.0226 | 0.2957 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0226 | 0.2957 | 0.5 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0226 | 0.2957 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0226 | 0.2957 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0226 | 0.2957 | 0.5 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0226 | 0.2957 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0226 | 0.2957 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0226 | 0.2957 | 0.5 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0226 | 0.2957 | 0.5 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0226 | 0.2957 | 0.5 |
Echinococcus granulosus | mitogen activated protein kinase | 0.0226 | 0.2957 | 1 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0226 | 0.2957 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase | 0.0226 | 0.2957 | 1 |
Brugia malayi | MAP kinase sur-1 | 0.0226 | 0.2957 | 0.5 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0226 | 0.2957 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0226 | 0.2957 | 0.5 |
Echinococcus multilocularis | mitogen activated protein kinase 3 | 0.0226 | 0.2957 | 1 |
Echinococcus granulosus | mitogen activated protein kinase 3 | 0.0226 | 0.2957 | 1 |
Schistosoma mansoni | serine/threonine protein kinase | 0.0226 | 0.2957 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0226 | 0.2957 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 0.0184 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | = 3.5481 um | PUBCHEM_BIOASSAY: qHTS Inhibitors of AmpC Beta-Lactamase (assay with detergent). (Class of assay: confirmatory) [Related pubchem assays: 1002 (Confirmation Concentration-Response Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent)), 585 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent) - a screen old NIH MLSMR collection), 584 (Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent) - a screen of the old NIH MLSMR collection), 1003 (Confirmation Cuvette-Based Assay for Inhibitors of AmpC Beta-Lactamase (assay with detergent))] | ChEMBL. | No reference |
Potency (functional) | = 39.8107 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide. (Class of assay: confirmatory) | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.